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Nitric oxide (NO) has been implicated in various
aspects of atherosclerosis and was shown to possess
both protective and cytotoxic properties (1). While
endothelial nitric oxide synthase (eNOS) is thought to
preserve endothelial function (2), inducible nitric
oxide synthase (iNOS) is involved in inflammation
and in the defense against infectious organisms (3, 4).
However, NO can also have damaging effects during
acute and chronic inflammatory conditions (4, 5). NO
reacts with several cellular oxidants to form highly
reactive nitrating radicals, which can oxidize lipids
and proteins (6). Hence, temporarily controlled iNOS
expression is thought to play a role in the defense
against infectious organisms, while chronic expres-
sion may be associated with inflammation (7).
Consistent with the inflammatory process of athero-
sclerosis, iNOS expression was detected in human
and rabbit atherosclerotic lesions and colocalizedwith
signs of lipid oxidation, suggesting that iNOS may
influence atherosclerosis (8–10). In contrast,
increased endothelial iNOS expression may over-
come the reduced eNOS expression of dysfunctional
endothelium and hence may restore endothelial func-
tion (2). Hence, the influence of iNOS expression in
different cell types in the artery wall on atheroscle-
rosis is not yet clear.
Two potentially functional polymorphisms, a 4-bp
insertion/deletion (q/y) in an AAAT/AAAAT repeat at
position y756 to y716 and a pentanucleotide CCTTT
repeat located 2.5 kbp upstream of the transcription
start site, have been detected in the promoter region
of the iNOS gene. Recent in vitro studies suggest that
the qallele of the 4-bp repeat polymorphism has a 25-
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fold higher transcriptional activity than the – allele in
certain cell types (11). Alleles with 14 repeats of the
CCTTT pentameric polymorphism were also shown to
respond with higher expression upon interleukin 1b
cytokine stimulation compared to alleles with shorter
pentameric repeats (12).
To study the potential role of iNOS in atheroscle-
rosis, we investigated the association of these two
iNOS polymorphisms with coronary artery disease
(CAD) in a case-control study involving 498 Cauc-
asians (342 men and 156 women). The study was
approved by the local Ethics Committee and all par-
ticipants gave written informed consent to participate.
The sample consisted of 260 consecutive patients
with angiographically documented CAD with )50%
stenosis in at least one coronary artery. The control
group consisted of 238 subjects without a history of
CAD, stroke, or peripheral vascular disease and was
recruited from angiographically negative individuals
and the general population. Controls were slightly
younger than cases (59.6"10.5 vs. 63.3"10.0 years)
and included more females (42% vs. 21%). However,
adjustment for age and sex did not alter the results
of our analysis. All the major known risk factors that
are not affected by CAD medication were associated
with CAD. History of hypertension (46.7% vs. 28.8%),
diabetes (20.7% vs. 3.5%) and smoking (73.6% vs.
47.6%) was found significantly more often in cases
than in controls. The body mass index (27.7"4.6 vs.
25.9"4.1 kg/m2) was higher in cases and high-density
lipoprotein cholesterol was lower in cases than in
controls (1.28"0.33 vs. 1.67"0.47 mmol/L). Due to
the high proportion of cases on lipid-lowering drugs
(81%), plasma total cholesterol (5.2"1.3 vs.
5.9"1.0 mmol/L) and low-density lipoprotein choles-
terol (3.2"1.1 vs. 3.5"0.9 mmol/L) were lower in CAD
patients than in controls.
For both polymorphisms, the genotype frequencies
in controls were in agreement with those predicted
by the Hardy-Weinberg equilibrium and were similar
to other studies in Caucasians (12–15). The allele fre-
quency for the minor qallele of the 4-bp insertion/
deletion polymorphism was 14% in controls (Figure
1A). Allele or genotype distribution was not statisti-
cally different in the case group (ps0.74) and carriers
of the qallele were not at higher risk for atheroscle-
rosis than non-carriers wodds ratio (OR) 1.10, confi-
dence interval (CI) 0.77–1.58x.
A total of 11 alleles were detected for the CCTTT
pentameric repeat polymorphism, ranging from 8
to 19 repeats (Figure 1B). Comparison of the genotype
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Figure 1 Allele and genotype frequencies of iNOS polymorphisms in the case-control study. (A) Genotype distribution of the
iNOS q/ypolymorphism in controls (gray) and in cases (black). (B) Allele distribution of the iNOS CCTTT repeat polymorphism
in controls (gray) and in cases (black). To amplify the region of the iNOS CCTTT repeat polymorphism (accession number
AF017634), primer U5553 ACCCCTGGAAGCCTACAACTGCAT and the fluorescent (Joe) labeled primer L5735 GCCA-
CTGCACCCTAGCCTGTCTCA were used. To amplify the region encompassing the 4-bp insertion/deletion (q/y) polymorphism
in iNOS (accession number D29675), the fluorescent (Joe)-labeled primer U299 CGCTCCAGTCTTGGTGACAGAATGA and L439
GCTTTGGTGGAATGGCAGGTAGGAT were used. The PCR products were then analyzed on an ABI Prism 310 Genetic Analyzer
using GeneScan 500 ROX as internal standard and allele assignment was done with ABI Genotyper software (all from Applied
Biosystems, Foster City, CA, USA).
distribution between controls and cases revealed no
significant difference (ps0.75). Since the 14-repeat
allele was previously associated with disease, we
analyzed the association of this allele with CAD sep-
arately. No significant difference between the two
groups was detected for the frequency of the 14-
repeat allele (ps0.54), or when we grouped into
alleles containing less than 14 repeats and alleles with
14 repeats and more (ps0.88, OR 1.02, CI 0.70–1.48).
Our data support earlier findings of a minor role of
the q/ypolymorphism in CAD. These studies inves-
tigated the association of the q/ypolymorphismwith
the severity of CAD in an autopsy study and an angio-
graphical study. Kunnas et al. (16) investigated the
association of the q/ypolymorphism in an autopsy
study and found that the q/ygenotype of iNOS was
associated with higher stenosis than the y/ygeno-
type. However, this was only true for a subgroup of
men )55 years of age and only for the left anterior
descending artery. No association of the q/ypoly-
morphism was observed in the right coronary artery
and in the left circumflex artery. Morris et al. (14)
investigated the association of theq/ypolymorphism
with the severity of CAD and found no association,
even when they tested for an interaction with smok-
ing, which is thought to enhance the oxidative burden
associated with increased iNOS expression. However,
this investigation showed an association of the
q/ypolymorphism with angina pectoris. Male carri-
ers of the qallele were more likely to have unstable
angina, higher plasma glucose and waist/hip ratios.
The qallele may therefore contribute to indices of
insulin resistance and angina severity in male CAD
patients, but does not play a major role in the path-
ogenesis of atherosclerosis.
While our data on the q/yiNOS polymorphism in
CAD support recent findings, we extended the inves-
tigation to the CCTTT polymorphism, which was also
shown to influence transcription of the iNOS gene
(12). However, no association with CAD was detected
in a logistic regression analysis for CCTTT alleles with
)13 repeats, or when we analyzed an association of
the 14-repeat allele alone, which was previously
shown to have the highest transcriptional activity (12).
Hence, the CCTTT polymorphism does not confer a
higher risk for CAD.
Although the power of this study is limited, a major
effect of the iNOS polymorphisms investigated on
CAD could have been detected. This study had a pow-
er of 80% to detect an odds ratio of 1.6 or larger for
the q/ypolymorphism and an OR of 1.9 for alleles
with G14 CCTTT repeats.
In summary, we show that the possibly functional
4-bp insertion/deletion (q/y) and the CCTTT repeat
polymorphism in the iNOS promoter do not play a
major role in the development of atherosclerosis.
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